The stock of Intellia Therapeutics Inc (NASDAQ:NTLA) is a huge mover today! About 548,404 shares traded hands or 69.94% up from the average. Intellia Therapeutics Inc (NASDAQ:NTLA) has risen 6.00% since September 10, 2016 and is uptrending. It has underperformed by 1.59% the S&P500.
The move comes after 7 months negative chart setup for the $478.52 million company. It was reported on Oct, 10 by Barchart.com. We have $12.52 PT which if reached, will make NASDAQ:NTLA worth $66.99M less.
Analysts await Intellia Therapeutics Inc (NASDAQ:NTLA) to report earnings on November, 3. After $-0.36 actual EPS reported by Intellia Therapeutics Inc for the previous quarter, Wall Street now forecasts -41.67% EPS growth.
Intellia Therapeutics Inc (NASDAQ:NTLA) Ratings Coverage
Out of 4 analysts covering Intellia Therapeutics (NASDAQ:NTLA), 4 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Intellia Therapeutics has been the topic of 5 analyst reports since May 31, 2016 according to StockzIntelligence Inc. The firm earned “Outperform” rating on Tuesday, May 31 by Credit Suisse. The rating was upgraded by Jefferies on Friday, August 5 to “Buy”. Jefferies initiated the shares of NTLA in a report on Tuesday, May 31 with “Hold” rating. The stock of Intellia Therapeutics Inc (NASDAQ:NTLA) earned “Outperform” rating by Wedbush on Tuesday, May 31. The firm has “Outperform” rating given on Friday, August 5 by Leerink Swann.
According to Zacks Investment Research, “Intellia Therapeutics, Inc. is a genome editing company focused on the development of curative therapeutics using a biological tool, CRISPR/Cas9 system. Intellia Therapeutics, Inc. is headquartered in Cambridge, Massachusetts.”
More news for Intellia Therapeutics Inc (NASDAQ:NTLA) were recently published by: Marketwatch.com, which released: “Plus the latest data from Realtor.com on 21 home markets across the US” on April 16, 2016. Globenewswire.com‘s article titled: “Intellia Therapeutics to Present at September Investor Healthcare Conferences” and published on September 01, 2016 is yet another important article.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.